Microcap Bearish Stocks: Ixia (NASDAQ:XXIA), Mitek Systems (NASDAQ:MITK), Tower Group International, Ltd. (NASDAQ:TWGP), Agenus Inc (NASDAQ:AGEN)

Ixia (NASDAQ:XXIA)’s stock had its “hold” rating reaffirmed by equities research analysts at Deutsche Bank in a research note issued to investors on Tuesday. They currently have a $12.00 target price on the stock, down from their previous target price of $16.00. Deutsche Bank’s target price indicates a potential upside of 1.61% from the company’s current price. Ixia (NASDAQ:XXIA), net profit margin is 4.20% and weekly performance is -3.22%. On last trading day company shares ended up $11.43. Analysts mean target price for the company is $14.00. Ixia (NASDAQ:XXIA), distance from 50-day simple moving average (SMA50) is -5.45%.

Mitek Systems, Inc. (NASDAQ:MITK), was the recipient of a significant decline in short interest in the month of May. As of May 15th, there was short interest totalling 6,481,725 shares, a decline of 14.3% from the April 30th total of 7,566,385 shares, Stock Ratings Network.com reports. Based on an average daily trading volume, of 415,233 shares, the days-to-cover ratio is presently 15.6 days. Approximately 24.2% of the company’s shares are short sold. Mitek Systems, Inc. (NASDAQ:MITK), fell 5.93% in last trading session and ended the day on $3.33. MITK, Gross Margin is 89.00% and its return on assets is -22.60%. Mitek Systems, Inc. (NASDAQ:MITK), quarterly performance is -13.95%.

Tower Group International, Ltd. (NASDAQ:TWGP), the insurer that agreed to be bought by ACP Re Ltd., plunged to a record low amid doubts over whether the deal will be completed. Tower Group International, Ltd. (NASDAQ:TWGP), shares moved down 11.11% in last trading session and was closed at $1.80, while trading in range of $1.62 – 1.85. Tower Group International, Ltd. (NASDAQ:TWGP), year to date (YTD) performance is -46.75%.

On June 26, 2014, Agenus Inc (NASDAQ:AGEN), an immuno-oncology company developing a portfolio of checkpoint modulators (CPMs), heat shock protein peptide-based vaccines, and adjuvants, announced promising Phase 2 results for HerpV, a synthetic vaccine candidate for the treatment of patients with genital Herpes Simplex Virus-2 (HSV-2). HerpV contains a defined mixture of peptides representing HSV-2 antigens plus Agenus’ QS-21 Stimulon® adjuvant. Agenus Inc (NASDAQ:AGEN), ended the last trading day at $3.22. Company weekly volatility is calculated as 9.69% and price to cash ratio as 2.73. Agenus Inc (NASDAQ:AGEN), showed a negative weekly performance of 6.12%.